BR112023023866A2 - Derivado de piperazina e seu uso na medicina - Google Patents

Derivado de piperazina e seu uso na medicina

Info

Publication number
BR112023023866A2
BR112023023866A2 BR112023023866A BR112023023866A BR112023023866A2 BR 112023023866 A2 BR112023023866 A2 BR 112023023866A2 BR 112023023866 A BR112023023866 A BR 112023023866A BR 112023023866 A BR112023023866 A BR 112023023866A BR 112023023866 A2 BR112023023866 A2 BR 112023023866A2
Authority
BR
Brazil
Prior art keywords
medicine
piperazine derivative
piperazine
derivative
manufacture
Prior art date
Application number
BR112023023866A
Other languages
English (en)
Inventor
Fei Ye
Hongzhu Chu
Wei Liu
wutong Deng
Yi Sun
Yonggang Wei
Yuqin Zhu
Original Assignee
Chengdu Baiyu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Baiyu Pharmaceutical Co Ltd filed Critical Chengdu Baiyu Pharmaceutical Co Ltd
Publication of BR112023023866A2 publication Critical patent/BR112023023866A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

derivado de piperazina e seu uso na medicina. o presente pedido se refere a um composto à base de piperazina e uma composição do mesmo, e ao seu uso na fabricação de um medicamento antitumoral.
BR112023023866A 2021-05-21 2022-05-20 Derivado de piperazina e seu uso na medicina BR112023023866A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN202110550437 2021-05-21
CN202110562428 2021-05-24
CN202110885041 2021-08-03
CN202111331120 2021-11-12
CN202210084201 2022-01-25
PCT/CN2022/094124 WO2022242750A1 (zh) 2021-05-21 2022-05-20 哌嗪衍生物及其在医药上的应用

Publications (1)

Publication Number Publication Date
BR112023023866A2 true BR112023023866A2 (pt) 2024-02-06

Family

ID=84141136

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023866A BR112023023866A2 (pt) 2021-05-21 2022-05-20 Derivado de piperazina e seu uso na medicina

Country Status (9)

Country Link
US (1) US20240158406A1 (pt)
EP (1) EP4342896A1 (pt)
JP (1) JP2024519088A (pt)
KR (1) KR20240012534A (pt)
CN (1) CN117279917A (pt)
AU (1) AU2022277493A1 (pt)
BR (1) BR112023023866A2 (pt)
CA (1) CA3217941A1 (pt)
WO (1) WO2022242750A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024032409A1 (zh) * 2022-08-09 2024-02-15 成都百裕制药股份有限公司 哌嗪类化合物在联合放疗治疗肿瘤中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544891A (ja) * 2010-12-08 2013-12-19 ヴァンダービルト ユニバーシティー ｍＧＬＵＲ５受容体のアロステリック調節剤としての二環式ピラゾール化合物
AU2011343477A1 (en) * 2010-12-17 2013-07-04 Vanderbilt University Bicyclic triazole and pyrazole lactams as allosteric modulators of mGluR5 receptors
CN103570725B (zh) * 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
HRP20230458T1 (hr) 2018-04-30 2023-07-21 Ribon Therapeutics Inc. Piridazinoni kao inhibitori parp7
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
CN112745312B (zh) * 2019-10-30 2022-08-30 沈阳中化农药化工研发有限公司 哒嗪酮异恶唑甲醚类化合物及其应用
IL292432A (en) * 2019-10-30 2022-06-01 Ribon Therapeutics Inc Pyridazinones as parp7 inhibitors
WO2021087018A1 (en) * 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors

Also Published As

Publication number Publication date
TW202246277A (zh) 2022-12-01
EP4342896A1 (en) 2024-03-27
CN117279917A (zh) 2023-12-22
US20240158406A1 (en) 2024-05-16
CA3217941A1 (en) 2022-11-24
JP2024519088A (ja) 2024-05-08
KR20240012534A (ko) 2024-01-29
AU2022277493A1 (en) 2023-11-23
WO2022242750A1 (zh) 2022-11-24

Similar Documents

Publication Publication Date Title
CO2023000186A2 (es) Derivados de quinoxalina como fármacos anti-cáncer
BR112023023866A2 (pt) Derivado de piperazina e seu uso na medicina
BR112016026205A8 (pt) moduladores de entrançamento de gene smn2, seu uso e seu processo de preparação, e composições farmacêuticas
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
AR070783A1 (es) Forma de cristal de derivados de fenilamina-pirimidina
BR112021022889A2 (pt) Derivados heterocíclicos fundidos
BR112023018348A2 (pt) Forma de cristal de composto de óxido de nitrogênio e piridina e uso da mesma
BR112022002112A2 (pt) Composições de probióticos à base de plantas fermentadas e processos de preparação das mesmas
BR112021019859A2 (pt) Vacinas de circovírus suíno tipo 3 (pcv3) e produção e seus usos
BR112018008076A2 (pt) derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos
BR112022016286A2 (pt) Compostos macrocíclicos, processo para sua preparação e composições farmacêuticas contendo-os
BR112018070370A2 (pt) glucono delta-lactona para tratamento de infecções fúngicas vaginais
CL2022000045A1 (es) Derivados de camptotecina con un resto disulfuro y un resto piperazina.
BR112021024546A2 (pt) Compostos tricíclicos e uso dos mesmos
BR112022020897A2 (pt) Forma de dosagem oral sólida compreendendo pomalidomida.
UY39257A (es) Composición farmacéutica acuosa de levilimab y su uso
BR112022011919A2 (pt) Triterpenoides sintéticos com substituintes à base de nitrogênio em c-17 e métodos de uso dos mesmos
TWD202991S (zh) 錶
TWD202982S (zh) 錶
CL2022002752A1 (es) Complejos cristalinos
BR112021026774A2 (pt) N-formilhidroxilaminas como inibidores da neprilisina (nep) e, em praticular, como inibidores mistos da aminopeptidase n (apn) e da neprilisina (nep)
JP1718770S (ja) テーブル
CL2023001138A1 (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo inhibidores de galectina-3
CL2023002052A1 (es) Derivados de pirazolamida
JP1731853S (ja) ベッドサイドテーブル